A detailed history of Bessemer Group Inc transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Bessemer Group Inc holds 100 shares of ARWR stock, worth $2,105. This represents 0.0% of its overall portfolio holdings.

Number of Shares
100
Previous 121 17.36%
Holding current value
$2,105
Previous $3,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$19.36 - $29.54 $406 - $620
-21 Reduced 17.36%
100 $2,000
Q2 2024

Aug 13, 2024

BUY
$21.87 - $28.24 $2,646 - $3,417
121 New
121 $3,000
Q4 2023

Feb 09, 2024

BUY
$21.2 - $31.03 $1,568 - $2,296
74 Added 569.23%
87 $3,000
Q3 2023

Nov 13, 2023

SELL
$26.2 - $36.08 $1,938 - $2,669
-74 Reduced 85.06%
13 $0
Q2 2023

Aug 10, 2023

BUY
$25.16 - $41.38 $2,188 - $3,600
87 New
87 $3,000
Q4 2022

Feb 13, 2023

BUY
$28.0 - $40.56 $0 - $0
0 New
0 $0

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.23B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Bessemer Group Inc Portfolio

Follow Bessemer Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bessemer Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bessemer Group Inc with notifications on news.